The case of Wells Pharma of Houston, LLC v. Zyla Life Sciences, LLC, now before the United States Supreme Court, highlights an issue that compounding pharmacies and 503B outsourcing facilities can no longer afford to view as theoretical. At its core, the case asks whether a private pharmaceutical manufacturer may use state unfair competition laws to challenge a compounder’s compliance with the federal Food, Drug, and Cosmetic Act and effectively step into the role of a federal regulator.

Can Competitors Enforce FDA Standards Through State Law

The complaint arises from Zyla’s allegation that Wells Pharma, a registered 503B outsourcing facility, compounded and distributed drug products that compete with Zyla’s FDA approved product without first obtaining traditional FDA approval. Zyla asserts that, because the compounded products were allegedly not lawfully exempt under Section 503B, their distribution violated state laws that prohibit the sale of unapproved drugs and therefore constituted unfair competition.

How 503A and 503B Compounding Exemptions Are Being Challenged

From a regulatory perspective, the legal theory is significant. The FDCA generally reserves enforcement authority to FDA. Yet Zyla’s lawsuit seeks to use state law as a parallel enforcement mechanism, arguing that when state statutes incorporate federal approval standards, private competitors may bring civil actions based on alleged noncompliance with FDA requirements. If that theory is upheld, compounding pharmacies and outsourcing facilities could face litigation not only from regulators, but also from brand manufacturers and competitors who claim that a compounded product falls outside the statutory exemptions.

‍

This is precisely the type of risk that makes careful compliance analysis under Sections 503A and 503B essential.

‍

This is precisely the type of risk that makes careful compliance analysis under Sections 503A and 503B essential. Whether a drug may be compounded, whether it is essentially a copy of a commercially available product, whether bulk substances are properly sourced, and whether all statutory conditions are met are not academic questions. They determine whether a product is lawfully on the market and whether the facility is insulated from both FDA enforcement and private litigation.

‍

In my practice, I routinely advise pharmacies and outsourcing facilities on these exact issues. That includes evaluating whether a compounded product qualifies for a statutory exemption, assessing advertising and labeling risk, reviewing supply chain and bulk substance sourcing, and responding to FDA inspections and Warning Letters. It also includes defending facilities when their compounding practices are challenged by regulators, boards of pharmacy, or increasingly, by competitors using civil litigation as a regulatory tool.

‍

The Wells Pharma case underscores that compounding compliance is no longer judged only by FDA in an administrative setting. It may now be scrutinized in court by adverse parties seeking to frame regulatory questions as unfair competition or consumer protection claims. In that environment, pharmacies and outsourcing facilities need counsel who understand both the scientific and legal dimensions of compounding, the structure of the FDCA, and the evolving use of state law to test federal compliance.

For compounders, the lesson is clear. Compliance must be proactive, well documented, and legally defensible.

For compounders, the lesson is clear. Compliance must be proactive, well documented, and legally defensible. And when questions arise about whether a product, process, or business model fits within the compounding exemptions, those questions should be addressed with experienced regulatory counsel before they become the basis for enforcement or litigation.

‍

This case is a reminder that compounding law is no longer confined to FDA guidance and inspectional observations. It is increasingly being shaped in the courts, and the consequences for getting it wrong can extend far beyond traditional regulatory action.

‍

Contact us today if you need a compounding pharmacy attorney to represent you or provide consultation.